55 related articles for article (PubMed ID: 34247209)
1. 'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.
Orsolini L; Corkery JM; Chiappini S; Guirguis A; Vento A; De Berardis D; Papanti D; Schifano F
Curr Neuropharmacol; 2020; 18(9):809-837. PubMed ID: 31933443
[TBL] [Abstract][Full Text] [Related]
2. Converging public health crises: substance use during the coronavirus disease 2019 pandemic.
Striley CW; Hoeflich CC
Curr Opin Psychiatry; 2021 Jul; 34(4):325-331. PubMed ID: 34001699
[TBL] [Abstract][Full Text] [Related]
3. General hospital admissions in young and middle-aged people who use psychoactive substances: Impact of Covid-19 lockdowns.
Perino J; Ramaroson H; Ong N; Bezin J; Gilleron V; Daveluy A; Tournier M
Int J Drug Policy; 2023 Aug; 118():104082. PubMed ID: 37336071
[TBL] [Abstract][Full Text] [Related]
4. Psychotropics and COVID-19: An analysis of safety and prophylaxis.
Javelot H; Straczek C; Meyer G; Gitahy Falcao Faria C; Weiner L; Drapier D; Fakra E; Fossati P; Weibel S; Dizet S; Langrée B; Masson M; Gaillard R; Leboyer M; Llorca PM; Hingray C; Haffen E; Yrondi A
Encephale; 2021 Dec; 47(6):564-588. PubMed ID: 34548153
[TBL] [Abstract][Full Text] [Related]
5. On why the COVID-19 pandemic has not changed the world.
Maboloc CR
J Public Health (Oxf); 2023 Jun; 45(2):e381. PubMed ID: 36617227
[TBL] [Abstract][Full Text] [Related]
6. [Position statement of the National Academy of Medicine for psychoactive substances consumption and diseases derived from their abuse].
Academia Nacional de Medicina
Gac Med Mex; 2010; 146(5):301-3. PubMed ID: 21348284
[No Abstract] [Full Text] [Related]
7. [An overview of natural entheogens].
Waeber M; Pozzetti GM; Donzé N
Rev Med Suisse; 2024 Apr; 20(868):722-725. PubMed ID: 38568066
[TBL] [Abstract][Full Text] [Related]
8. Fentanyl and its derivatives, xylazine, and benzodiazepines: new sources of risk for acute poisonings.
Cárdenas-Quesada J; Torrens M; Farré M
Emergencias; 2023 Oct; 35(5):400. PubMed ID: 37801427
[No Abstract] [Full Text] [Related]
9. Substance use disorders during the COVID-19 pandemic: looking for new innovative approaches.
Piersanti V; Consalvo F; Marinelli E
Acta Biomed; 2022 Mar; 93(1):e2022081. PubMed ID: 35315387
[TBL] [Abstract][Full Text] [Related]
10. The health threat of drugs of abuse adulteration by new psychoactive substances.
Minutillo A; Palmi I; Mastrobattista L
Clin Ter; 2019; 170(6):e425-e426. PubMed ID: 31696904
[TBL] [Abstract][Full Text] [Related]
11. An expanding world of new psychoactive substances-designer benzodiazepines.
Zawilska JB; Wojcieszak J
Neurotoxicology; 2019 Jul; 73():8-16. PubMed ID: 30802466
[TBL] [Abstract][Full Text] [Related]
12. New Psychoactive Substances consumption and their monito- ring during Covid-19 pandemic.
Di Trana A; La Maida N
Clin Ter; 2021 Jul; 172(4):271-272. PubMed ID: 34247209
[TBL] [Abstract][Full Text] [Related]
13. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
Napoletano S; Basile G; Lo Faro AF; Negro F
Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
[TBL] [Abstract][Full Text] [Related]
14. New and Emerging Illicit Psychoactive Substances.
Graddy R; Buresh ME; Rastegar DA
Med Clin North Am; 2018 Jul; 102(4):697-714. PubMed ID: 29933824
[TBL] [Abstract][Full Text] [Related]
15. Increasing diversion of prescribed benzodiazepines and Z-drugs to new psychoactive substances.
Del Rio A; Graziano S; Tittarelli R; Umani-Ronchi F
Clin Ter; 2021 Mar; 172(2):116-118. PubMed ID: 33763670
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
